RTNB yields 2000000.00% · ABBV yields 3.06%● Live data
📍 RTNB pulled ahead of the other in Year 1
Combined, RTNB + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RTNB + ABBV for your $10,000?
root9B Holdings, Inc. provides cybersecurity and business advisory services primarily in regulatory risk mitigation in the United States and internationally. The company's Cyber Solutions segment offers cyber security, advanced technology training, operational support, and consulting services. This segment provides cyber operations assessments, analysis and testing, cyber training, forensics, exploitation, and strategic defense planning services. Its Business Advisory Solutions segment offers anti-money laundering (AML) operational, investigative, and remediation services, as well as AML risk advisory and consulting services in the areas of risk, data, organizational change, and cyber. This segment also conducts high-end investigations with expertise in services ranging from complex financial crime and intellectual property issues to conduct anti-bribery investigations or due diligence on a potential partner or customer. root9B Holdings, Inc. serves Fortune 500 companies, medium-sized businesses, and governmental entities. The company was formerly known as root9B Technologies, Inc. and changed its name to root9B Holdings, Inc. in December 2016. root9B Holdings, Inc. was founded in 1995 and is based in Phoenix, Arizona.
Full RTNB Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.